Rising focus of government & non-government institutions on creating awareness is expected to drive market expansion in the near future at a CAGR of 11.20% during the forecast period 2023 to 2032

Market Research Future (MRFR) has published on the “Global Opioid Use Disorder Market”.

The opioid use disorder market is estimated to register a CAGR of 11.20% during the forecast period of 2023 to 2032.

MRFR recognizes the following companies as the key players in the opioid use disorder market— Alkermes, Inc., Indivior PLC, BioDelivery Sciences International, Inc., Orexo US, Inc., Titan Pharmaceuticals, Inc., Omeros Corporation, Camurus, Hikma Pharmaceuticals PLC, AstraZeneca plc, Viatris Inc.

Market Highlights

The opioid use disorder market is accounted to register a CAGR of 11.20% during the forecast period and is estimated to reach USD 8.05 billion by 2032.

The opioid use disorder (OUD) market faces a complex landscape. Market drivers include rising opioid addiction rates, expanding government initiatives for addiction treatment, and advancements in medication-assisted treatment. Restraints involve societal stigma, regulatory hurdles, and limited access to treatment. Opportunities lie in innovative therapies, telemedicine solutions, and increased awareness. Challenges include patient adherence, healthcare disparities, and the opioid crisis' multifaceted nature, demanding comprehensive strategies for effective management.

Segment Analysis

The opioid use disorder market has been segmented based on Drug Type, Age Group, Route of Administration and Distribution Channel.

On the basis of Drug Type, the market is segmented into Buprenorphine, Naltrexone, and Methadone. The methadone segment was attributed to holding the largest market share in 2022. With its long-acting opioid agonist properties, it effectively helps alleviate withdrawal symptoms and cravings. Its established track record and proven efficacy in managing OUD make it a dominant choice, especially in tightly regulated clinical environments. On the other hand, Buprenorphine, known for its partial agonist properties, is the rapidly expanding category, reducing the chances of overdose and abuse.

Based on Age Group, the opioid use disorder market has been segmented into 19 to 40, 41 to 60, and 61 and over. The 41 to 60 segment was expected to hold the largest market share in 2022. This demographic dominance can be attributed to factors such as a higher likelihood of chronic pain issues, increased exposure to prescription opioids for medical reasons, and a longer duration of potential opioid use. However, the fastest-growing category is the age group of 19 to 40, reflecting a concerning trend of rising opioid misuse among younger individuals.

Based on Route of Administration, the opioid use disorder market has been segmented into Intravenous and Oral. The oral segment was expected to hold the largest market share in 2022. Oral administration is commonly chosen for OUD treatment due to its practicality, safety, and ease of patient compliance, avoiding complications linked to intravenous methods like infection risks and the necessity for specialized medical supervision. On the other hand, the most rapidly expanding category is intravenous administration, driven by the urgency and immediate attention often necessary in emergency situations or critical cases of opioid dependence.

Based on Distribution Channel, the opioid use disorder market has been segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The hospital pharmacies segment was expected to hold the largest market share in 2022. The treatment of OUD can be challenging, often needing specific medications and close supervision. Hospital pharmacies, staffed by healthcare professionals, help with medication administration and management, giving them a leading role. In contrast, online pharmacies are the fastest-growing sector, reflecting the rise of telehealth services in healthcare. Online pharmacies offer a convenient and easily accessible option for those seeking OUD treatment.

Access full report @ https://www.marketresearchfuture.com/reports/opioid-use-disorder-market-21681

Regional Analysis

The opioid use disorder market, based on region, has been divided into North America, Europe, Asia-Pacific, and Rest of the World. North America consists of the US and Canada. The Europe opioid use disorder market comprises Germany, France, the UK, Italy, Spain, and the rest of Europe. The opioid use disorder market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World opioid use disorder market comprises the Middle East, Africa, and Latin America.

The largest market share for opioid use disorder was maintained by the North American regional sector. This increase is attributed to the region has faced a significant opioid crisis, with high rates of opioid misuse, addiction, and overdose deaths, driving demand for treatment services and medications. Additionally, North America has a well-established healthcare infrastructure with robust addiction treatment programs, including medication-assisted treatment (MAT) and counseling services.

Moreover, the Europe market has been persistently growing over the forecast period. The demand for opioid use disorder is driven by advancements in medical research and pharmacotherapies, which have led to the development and adoption of new medications and treatment approaches for OUD in Europe. Moreover, there has been a growing emphasis on harm reduction strategies and integrated healthcare models, which have contributed to the expansion of OUD treatment options and services in the region.

Additionally, Asia Pacific is anticipated to experience the quickest growth in the opioid use disorder (OUD) market due to several factors. Firstly, there is a growing recognition of the increasing prevalence of OUD in the region, driven by factors such as changing demographics, urbanization, and shifts in lifestyle and healthcare practices. Additionally, there is an increasing focus on mental health and substance abuse disorders in many Asia Pacific countries, leading to greater awareness and demand for OUD treatment services.

Furthermore, the rest of the world's opioid use disorder market is divided into the Middle East, Africa, and Latin America. This growth is attributed to the cultural attitudes and stigmas surrounding substance abuse and addiction vary across these regions, affecting the prevalence of OUD and the demand for treatment options. Additionally, healthcare infrastructure and access to addiction treatment services may vary widely, impacting the availability and adoption of OUD therapies. Economic factors, political stability, and regulatory environments also play significant roles in shaping the landscape of OUD treatment markets in these regions.

Key Findings of the Study

• The opioid use disorder market is expected to reach USD 8.05 billion by 2032, at a CAGR of 11.20% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market due to urbanization and shifts in lifestyle and healthcare practices.


• Based on drug type, the methadone segment was attributed to holding the largest market in 2022, with an approximate market share of 40–65%.


• Alkermes, Inc., Indivior PLC, BioDelivery Sciences International, Inc., Orexo US, Inc., Titan Pharmaceuticals, Inc., Omeros Corporation, Camurus, Hikma Pharmaceuticals PLC, AstraZeneca plc, and Viatris Inc. are the key market players.